Impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center

• Published in: Pediatric pulmonology 2019-10, Vol.54 (10), p.1591-1595
• Main Authors: Wright, Brittany A., Singh, Sachinkumar B., Schultz, Jordan L., Ramsey, Laura J., Spading, Kimberly A., Mascardo, Lisa A., Starner, Timothy D.
• Format: Article
• Language: English
• Subjects: Adolescent; Child; Child, Preschool; cystic fibrosis; Cystic Fibrosis - drug therapy; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Pharmaceutical Services; Pharmacies; pharmacology; Prior Authorization
• ISSN: 8755-6863; 1099-0496
• DOI: 10.1002/ppul.24446

Background This study was undertaken to determine if the presence of a clinical pharmacy team impacted patients’ access to cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Methods A retrospective chart review of electronic medical records from the University of Iowa Hospitals and Clinics (UIHC) was conducted. Data were collected regarding the timing of prior authorization (PA) submissions and approvals from 2012 to 2018. The Wilcoxon rank‐sum test was used to compare the meantime (days) between prescription and PA submission dates, and PA submission and approval date for all patients included in the analysis. Comparisons were made for pre‐ and postpharmacy services eras as well as the UIHC Specialty Pharmacy versus a non‐UIHC Specialty Pharmacy. Results Sixty‐three patients were included in the final analysis. The average time between prescription date and PA submission was 12.5 days (standard deviation [SD] = 17.4 days) in the preclinical pharmacy services era and 3.5 days (SD = 5.8 days; P = .028) in the postclinical pharmacy services era. The average time to PA submission significantly decreased from 9.8 days (SD = 13.1 days) to 1.3 days (SD = 4.2 days; P